MicroRNA-205 Mediates Proteinase-Activated Receptor 2 (PAR₂) -Promoted Cancer Cell Migration

References

• Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science (New York, N.Y.) 2011;331(6024):1559–64.
   PubMed Web of Science ®Google Scholar
• Gieseler F, Ungefroren H, Settmacher U, Hollenberg MD, Kaufmann R. Proteinase-activated receptors (PARs) – focus on receptor-receptor-interactions and their physiological and pathophysiological impact. Cell Commun Signal 2013;11:86.
   PubMed Web of Science ®Google Scholar
• Versteeg HH, Schaffner F, Kerver M, Ellies LG, Andrade-Gordon P, Mueller BM, Ruf W. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res 2008;68(17):7219–7227.
   PubMed Web of Science ®Google Scholar
• Elste AP, Petersen I. Expression of proteinase-activated receptor 1–4 (PAR 1–4) in human cancer. J Mol Histol 2010;41(2–3):89–99.
   PubMed Web of Science ®Google Scholar
• Zhao P, Metcalf M, Bunnett NW. Biased signaling of protease-activated receptors. Front Endocrinol 2014;5:67.
   PubMed Web of Science ®Google Scholar
• Adams MN, Ramachandran R, Yau MK, Suen JY, Fairlie DP, Hollenberg MD, Hooper JD. Structure, function and pathophysiology of protease activated receptors. Pharmacol Therapeut 2011;130(3):248–282.
   PubMed Web of Science ®Google Scholar
• Ma Y, Bao-Han W, Lv X, Su Y, Zhao X, Yin Y, Zhang X, Zhou Z, MacNaughton WK, Wang H. MicroRNA-34a mediates the autocrine signaling of PAR2-activating proteinase and its role in colonic cancer cell proliferation. PloS One 2013;8(8):e72383.
   PubMed Web of Science ®Google Scholar
• Yang L, Ma Y, Han W, Li W, Cui L, Zhao X, Tian Y, Zhou Z, Wang W, Wang H. Proteinase-activated receptor 2 promotes cancer cell migration through RNA methylation-mediated repression of miR-125b. J Biol Chem. 2015;290(44):26627–26637.
   PubMed Web of Science ®Google Scholar
• Su S, Li Y, Luo Y, Sheng Y, Su Y, Padia RN, Pan ZK, Dong Z, Huang S. Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene 2009;28(34):3047–3057.
   PubMed Web of Science ®Google Scholar
• Nasri I, Bonnet D, Zwarycz B, d'Aldebert E, Khou S, Mezghani-Jarraya R, Quaranta M, Rolland C, Bonnart C, Mas E, Ferrand A, Cenac N, Magness S, Van Landeghem L, Vergnolle N, Racaud-Sultan C. PAR2-dependent activation of GSK3beta regulates the survival of colon stem/progenitor cells. Am J Physiol Gastrointest Liver Physiol. 2016;311(2):G221–G236.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang J, Zhou H, Yu X, Hu L, Meng F, Jiang S. Effects of calcium signaling on coagulation factor VIIa-induced proliferation and migration of the SW620 colon cancer cell line. Mol Med Rep 2014;10(6):3021–3026.
   PubMed Web of Science ®Google Scholar
• Hu L, Xia L, Zhou H, Wu B, Mu Y, Wu Y, Yan J. TF/FVIIa/PAR2 promotes cell proliferation and migration via PKCalpha and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620. Tumour Biol: J Int Soc Oncodev Biol Med 2013;34(5):2573–81.
   PubMedGoogle Scholar
• Izzotti A, Carozzo S, Pulliero A, Zhabayeva D, Ravetti JL, Bersimbaev R. Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and prevention. Am J Cancer Res 2016;6(7):1461–93.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Chin KY, Das S. miRNA-regulated cancer stem cells: understanding the property and the role of miRNA in carcinogenesis. Tumour Biol: J Int Soc Oncodev Biol Med. Tumour Biol. 2016;37(10):13039–48.
   PubMedGoogle Scholar
• Kinoshita T, Yip KW, Spence T, Liu FF. MicroRNAs in extracellular vesicles: potential cancer biomarkers. J Hum Genet. 2017;62(1):67–74.
   PubMed Web of Science ®Google Scholar
• Vosgha H, Salajegheh A, Smith RA, Lam AK. The important roles of miR-205 in normal physiology, cancers and as a potential therapeutic target. Curr Cancer Drug Targets. 2014;14(7):621–637.
   PubMed Web of Science ®Google Scholar
• Orang AV, Safaralizadeh R, Hosseinpour Feizi MA. Insights into the diverse roles of miR-205 in human cancers. Asian Pac J Cancer Prevent 2014;15(2):577–583.
   PubMedGoogle Scholar
• Qin AY, Zhang XW, Liu L, Yu JP, Li H, Wang SZ, Ren XB, Cao S. MiR-205 in cancer: an angel or a devil? Eur J Cell Biol. 2013;92(2):54–60.
   PubMed Web of Science ®Google Scholar
• Mao Y, Wu S, Zhao R, Deng Q. MiR-205 promotes proliferation, migration and invasion of nasopharyngeal carcinoma cells by activation of AKT signalling. J Int Med Res 2016;44(2):231–240.
   PubMed Web of Science ®Google Scholar
• Niu K, Shen W, Zhang Y, Zhao Y, Lu Y. MiR-205 promotes motility of ovarian cancer cells via targeting ZEB1. Gene. 2015;574(2):330–6.
   PubMed Web of Science ®Google Scholar
• Larzabal L, de Aberasturi AL, Redrado M, Rueda P, Rodriguez MJ, Bodegas ME, Montuenga LM, Calvo A. TMPRSS4 regulates levels of integrin alpha5 in NSCLC through miR-205 activity to promote metastasis. Br J Cancer 2014;110(3):764–774.
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev. Drug Discov 2012;11(1):69–86.
   PubMed Web of Science ®Google Scholar
• Uchima Y, Sawada T, Hirakawa K. Action of antiproteases on pancreatic cancer cells. J Pancreas 2007;8(4 Suppl):479–487.
   PubMedGoogle Scholar
• Miyata S, Koshikawa N, Yasumitsu H, Miyazaki K. Trypsin stimulates integrin alpha(5)beta(1)-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2. J Biol Chem 2000;275(7):4592–4598.
   PubMed Web of Science ®Google Scholar
• Su N, Qiu H, Chen Y, Yang T, Yan Q, Wan X. miR-205 promotes tumor proliferation and invasion through targeting ESRRG in endometrial carcinoma. Oncol Rep. 2013;29(6):2297–2302.
   PubMed Web of Science ®Google Scholar
• Majid S, Saini S, Dar AA, Hirata H, Shahryari V, Tanaka Y, Yamamura S, Ueno K, Zaman MS, Singh K, Chang I, Deng G, Dahiya R. MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res. 2011;71(7):2611–2621.
   PubMed Web of Science ®Google Scholar
• Hamamoto J, Soejima K, Yoda S, Naoki K, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Yasuda H, Hayashi Y, Sakamoto M, Takebayashi T, Betsuyaku T. Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. Mol Med Rep. 2013;8(2):456–462.
   PubMed Web of Science ®Google Scholar
• Solomides CC, Evans BJ, Navenot JM, Vadigepalli R, Peiper SC, Wang ZX. MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis. Acta Cytol 2012;56(6):645–654.
   PubMed Web of Science ®Google Scholar
• Eyking A, Reis H, Frank M, Gerken G, Schmid KW, Cario E. MiR-205 and MiR-373 are associated with aggressive human mucinous colorectal cancer. PloS One 2016;11(6):e0156871.
   PubMed Web of Science ®Google Scholar
• Greene SB, Herschkowitz JI, Rosen JM. The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer. RNA Biol 2010;7(3):300–304.
   PubMed Web of Science ®Google Scholar
• Yu J, Ryan DG, Getsios S, Oliveira-Fernandes M, Fatima A, Lavker RM. MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. Proc Natl Acad Sci U S A 2008;105(49):19300–19305.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Menard S, Croce CM, Tagliabue E. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009;69(6):2195–2200.
   PubMed Web of Science ®Google Scholar
• Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, Valdagni R, Daidone MG, Zaffaroni N. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009;69(6):2287–2295.
   PubMed Web of Science ®Google Scholar
• Syn N, Wang L, Sethi G, Thiery JP, Goh BC. Exosome-mediated metastasis: from epithelial-mesenchymal transition to escape from immunosurveillance. Trends Pharmacol Sci 2016;37(7):606–617.
   PubMed Web of Science ®Google Scholar
• Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 2007;213(2):374–383.
   PubMed Web of Science ®Google Scholar
• Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10(5):593–601.
   PubMed Web of Science ®Google Scholar
• Cao LY, Yang J, Fu XG, Lin YH, Lin F, Huang BY. [The MicroRNA miR-205 inhibits epithelial-messenchymal transition in HK-2 cells by down-regulating ZEB1 and ZEB2 expressions]. J Sout Med Univ 2016;36(12):1700–1705.
   Google Scholar
• Zhang Z, Lanz RB, Xiao L, Wang L, Hartig SM, Ittmann MM, Feng Q, He B. The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors. Oncotarget. 2016;7(25):37993–38003.
   PubMed Web of Science ®Google Scholar
• Saetrom P, Biesinger J, Li SM, Smith D, Thomas LF, Majzoub K, Rivas GE, Alluin J, Rossi JJ, Krontiris TG, Weitzel J, Daly MB, Benson AB, Kirkwood JM, O'Dwyer PJ, Sutphen R, Stewart JA, Johnson D, Larson GP. A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res 2009;69(18):7459–7465.
   PubMed Web of Science ®Google Scholar
• Wakefield LM, Hill CS. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat Rev Cancer 2013;13(5):328–341.
   PubMed Web of Science ®Google Scholar
• Kang MH, Kim JS, Seo JE, Oh SC, Yoo YA. BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Exp Cell Res. 2010;316(1):24–37.
   PubMed Web of Science ®Google Scholar
• Voorneveld PW, Kodach LL, Jacobs RJ, Liv N, Zonnevylle AC, Hoogenboom JP, Biemond I, Verspaget HW, Hommes DW, de Rooij K, van Noesel CJ, Morreau H, van Wezel T, Offerhaus GJ, van denBrink GR, Peppelenbosch MP, Ten Dijke P, Hardwick JC. Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK. Gastroenterology. 2014;147(1):196–208.e13.
   PubMed Web of Science ®Google Scholar
• Nagaraj NS., Datta PK. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs. 2010;19(1):77–91.
   PubMed Web of Science ®Google Scholar
• Zeeh F, Witte D, Gadeken T, Rauch BH., Grage-Griebenow E, Leinung N, Fromm SJ, Stolting S, Mihara K, Kaufmann R, Settmacher U, Lehnert H, Hollenberg MD, Ungefroren H. Proteinase-activated receptor 2 promotes TGF-beta-dependent cell motility in pancreatic cancer cells by sustaining expression of the TGF-beta type I receptor ALK5. Oncotarget. 2016;7(27):41095–41109.
   PubMed Web of Science ®Google Scholar
• Chung H, Ramachandran R, Hollenberg MD, Muruve DA. Proteinase-activated receptor-2 transactivation of epidermal growth factor receptor and transforming growth factor-beta receptor signaling pathways contributes to renal fibrosis. J Biol Chem. 2013;288(52):37319–37331.
   PubMed Web of Science ®Google Scholar